Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.60 |
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | BTK | Q06187 | 4/20 | 0.60 |
| ▸ | ITK | Q08881 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | STK16 | O75716 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.60 |
| ▸ | MST1R | Q04912 | 2/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.60 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.60 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.60 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.60 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.60 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213004 | 1.00 | SYK (0.60) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2520950 | 0.96 | SYK (0.61) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2525311 | 0.94 | SYK (0.63) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2522493 | 0.92 | SYK (0.56) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL12213007 | 0.92 | SYK (0.56) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL12213131 | 0.91 | SYK (0.59) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL12213000 | 0.90 | SYK (0.57) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2525435 | 0.90 | SYK (0.57) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2525507 | 0.89 | SYK (0.57) | SYKEGFRBTKITKADORA3 | |
| SCHEMBL2519004 | 0.88 | SYK (0.63) | SYKEGFRBTKITKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | claimed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | SYK 1871/4885EGFR 3393/4885BTK 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.